Sturge-Weber Syndrome Market Analysis

Global Sturge Weber Syndrome Market Overview

The Sturge Weber Syndrome Market is evaluated to grow at a CAGR of 5.10%. With the support from major drivers such as the rising prevalence of glaucoma, epilepsy, the Sturge Weber Syndrome Market will rise to significant value in the studied forecast period 2022-2030. Sturge Weber syndrome is a congenital disorder. It is characterized by eye complications, port-wine stain birthmark, and others.

As per the Sturge Weber Syndrome Market Analysis by MRFR, it is estimated that North America will lead the market. However, the Asia-Pacific region is projected to record the fastest growth in the upcoming years. According to World Health Organisation (WHO), approximately 30 million people across the European Union countries were having a rare disease. As a result, the growth of the Sturge Weber Syndrome Market is evaluated to simultaneously increase in the forecast period.

COVID-19 Analysis

The increase in the spread of COVID-19 disease led to huge havoc across the world. Due to this, the focus of the healthcare sector shifted to contain the spread. Furthermore, it also reduced the Sturge Weber Syndrome Market Growth significantly. However, with the rising emphasis and support by the government, it is anticipated the market will have considerable growth. Also, the steps taken by the key players will further enhance the market growth.

Sturge Weber Syndrome Market Trends

Market Drivers

Important factors such as increasing cases of rare diseases and rising awareness among people will drive the market growth. Also, the increasing technological advancements are estimated to enhance the Sturge Weber Syndrome Global Market Growth.

Restraints

Factors such as high costs for the treatment of sturge weber syndrome are evaluated to slow down the growth of the Sturge Weber Syndrome Market. Along with that, the side effects related caused by the drugs for the treatment are also estimated to restraint the market growth.

Opportunities

There are various opportunities such as increasing Sturge Weber Syndrome Global Market Trends with increasing funds by the support from governments and key players. These funds will be helpful for development and research to boost the Sturge Weber Syndrome Market Outlook.

Challenges

One of the major challenges for the Sturge Weber Syndrome Market is the disruption in the supply chain. Along with that, problems can occur in the development, and research is speculated to hinder the market growth.

Cumulative Analysis

According to Sturge Weber Syndrome Market Forecast, the market value is estimated to reach up to USD 230 Million. The Compound Annual Growth Rate (CAGR) is further evaluated to rise up to 5.5% by the end of the projected forecast period 2021-2028. Increasing awareness for the treatment of rare diseases will impact the market positively.

Value Chain Analysis

With the improvement in the Sturge Weber Syndrome Market Trends and technological advancements, the market will expand in the future. Also, the rising demand for better healthcare facilities and crucial strategies by key players are estimated to enhance the value chain of the market.

Global Sturge-Weber syndrome market Size, by End User, 2017 (USD Million)   

Source: MRFR Analysis

Sturge Weber Syndrome Market Segment Insights

Sturge Weber Syndrome Type Insights

On the basis of Type, the market is divided into Type 2, Type3, and Type 1.

Sturge Weber Syndrome End User Insights

On the basis of end-user, the Sturge Weber Syndrome Marketis divided into Diagnostic Centres, Clinics and Hospitals, and Others. In the year 2017, the clinics and hospitals segment accounted for a market value of USD 1,257.72 Million. Therefore, the revenue of this section will further increase in the forthcoming years.

Sturge Weber Syndrome Treatment Insights

On the basis of Treatment, the Sturge Weber Syndrome Market is divided into Surgical Procedure, and Laser Therapy. The laser treatment is further divided into medication which is again divided into Antiglaucoma and Antiepileptic. Furthermore, Antiglaucoma is divided into carbonic Anhydrase Inhibitors, Beta Antagonist Eye Drops, and Latanoprost. 

The Diagnosis segment of the Sturge Weber Syndrome Global Market is divided into Skull Radiography, Magnetic resonance imaging (MRI), Electroencephalogram, and Computed Topography.

Sturge Weber Syndrome Regional Insights

Geographically, the Sturge Weber Syndrome Market Sizeis divided into Asia-Pacific, North America, Africa, and the Middle East, and Europe. According to the Sturge Weber Syndrome Global Market Analysis by MRFR, North America will dominate the market in the upcoming years of the forecast period 2021-2028. The increasing research for the funds for treating rare diseases and technological development is the crucial driver.

Secondly, Europe is estimated to have the second-largest Sturge Weber Syndrome Market Sharein the estimated forecast period. Several driving factors such as increasing expenditure for healthcare, support from the government are fuelling the market growth in this region.

However, the Asia-Pacific region is evaluated to have the fastest growth in the upcoming years. Due to the rising demand for early diagnosis and improvement in technology, the market will record immense growth. Also, countries such as India, China, Japan, etc. are contributing to the immense Sturge Weber Syndrome Global Market Growth. Also, the supportive funds and initiatives by the government will further boost the market growth in Asia-Pacific.

Asia-Pacific Sturge-Weber syndrome market Share, by Country, 2017 (%)  

Source: MRFR Analysis

Competitive Landscape

The key players in the Sturge Weber Syndrome Market apply various market strategies to improve their business. They do mergers, partnerships, collaboration, new ventures, and product launches, acquisitions, etc. Some of the important key players in the Sturge Weber Syndrome Market are as follows.

• Shire (Ireland)


• ElectoCore LLC (US)


• GW Pharmaceuticals, PLC (US)


• Johnson and Johnson (US)


• Pfizer Inc. (US)


• Abbot (US)


• Aleva Neurotherapeutics SA (Switzerland)


• Hoffman-La Roche AG


• Sanofi (France)


• UCB SA (Belgium)

• Shire in 2017 announced its FDA approval for its product called MYDAYIS. This is used for treating patients from the age of 13 and above.


• UCB SA in 2018 acquired a nasal spray from a company called Promixagen. This acquisition will help UCB SA to enhance its portfolio in epilepsy treatment.


• Novartis AG in 2018 acquired a company called AveXis. This acquisition is done for widening the portfolio in the sector of neuroscience and gene therapy.

Report Overview

The overview of the Sturge Weber Syndrome Market Outlook is as follows.

• Market Overview


• COVID-19 Analysis


• Dynamics of the Market


• Value Chain Analysis


• Market Segmentation


• Regional Analysis


• Competitive Analysis


• Recent Development

Report Score and Segmentation

The report score is to provide significant information to support the Sturge Weber Syndrome Market Analysis. It highlights valuable information such as drivers, opportunities, challenges, etc. the information provided in this report is collected from secondary and primary sources.

• Study Period- 2021-2028


• Base Year-2021


• Forecast Period- 2021-2028


• Historical Period-2017-2020

Sturge Weber Syndrome Market Segmentation

Sturge Weber Syndrome Type Outlook

• Type I


• Type II


• Type III

Sturge Weber Syndrome End-User Outllok

• Clinics and Hospitals


• Diagnostic Centres


• Others

Sturge Weber Syndrome Diagnosis and Treatment Outlook

• 
  Diagnosis
  
  
  
  • Electroencephalogram (EEG)
  
  
  • Skull Radiography
  
  
  • Computer Tomography (CT) Scan
  
  
  • Magnetic Resonance Imaging (MRI)
  
  
  
  


• 
  Treatment
  
  
  
  • Surgical Procedure
  
  
  • Laser Therapy
  
  
  • 
    Medication
    
    
    
    • 
      Antiglaucoma
      
      
      
      • Carbonic Anhydrase Inhibitors
      
      
      • Beta Antagonist Eye Drops
      
      
      • Latanoprost
      
      
      • Others
      
      
      
      
    
    
    • Antiepileptic
    
    
    
    
  
  
  
  

Sturge Weber Syndrome Region Outlook

• North America


• Asia-Pacific


• Africa and the Middle East


• Europe